These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 15059112)

  • 21. Analytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma.
    Holmstrom S; Buchholz P; Walt J; Wickstrøm J; Aagren M
    Curr Med Res Opin; 2005 Nov; 21(11):1875-83. PubMed ID: 16307709
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cystoid macular edema in a low-risk patient after switching from latanoprost to bimatoprost.
    Carrillo MM; Nicolela MT
    Am J Ophthalmol; 2004 May; 137(5):966-8. PubMed ID: 15126179
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ocular effects of topical 0.03% bimatoprost solution in normotensive feline eyes.
    Regnier A; Lemagne C; Ponchet A; Cazalot G; Concordet D; Gelatt KN
    Vet Ophthalmol; 2006; 9(1):39-43. PubMed ID: 16409244
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevention of dermatologic side effects of bimatoprost 0.03% topical therapy.
    Centofanti M; Oddone F; Chimenti S; Tanga L; Citarella L; Manni G
    Am J Ophthalmol; 2006 Dec; 142(6):1059-60. PubMed ID: 17157592
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The cost-effectiveness of bimatoprost, latanoprost and timolol in treatment of primary open angle glaucoma in five European countries.
    Holmstrom S; Buchholz P; Walt J; Wickstrøm J; Aagren M
    Curr Med Res Opin; 2006 May; 22(5):897-905. PubMed ID: 16709311
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy.
    Denis P; Lafuma A; Khoshnood B; Mimaud V; Berdeaux G
    Curr Med Res Opin; 2007 Mar; 23(3):601-8. PubMed ID: 17355741
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A 6-month assessment of bimatoprost 0.03% vs timolol maleate 0.5%: hypotensive efficacy, macular thickness and flare in ocular-hypertensive and glaucoma patients.
    Martin E; Martinez-de-la-Casa JM; Garcia-Feijoo J; Troyano J; Larrosa JM; Garcia-Sanchez J
    Eye (Lond); 2007 Feb; 21(2):164-8. PubMed ID: 16254590
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased periocular pigmentation with ocular hypotensive lipid use in African Americans.
    Sodhi PK; Verma L; Ratan SK
    Am J Ophthalmol; 2004 Apr; 137(4):783. PubMed ID: 15059736
    [No Abstract]   [Full Text] [Related]  

  • 29. Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma.
    Christiansen GA; Nau CB; McLaren JW; Johnson DH
    Ophthalmology; 2004 Sep; 111(9):1658-62. PubMed ID: 15350319
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bimatoprost versus timolol and dorzolamide.
    Tressler CS
    Ophthalmology; 2005 Feb; 112(2):357-8; author reply 358-9. PubMed ID: 15691575
    [No Abstract]   [Full Text] [Related]  

  • 31. [Cystoid macular edema in a pseudophakic patient after several glaucoma procedures. Is local therapy with bimatoprost the reason?].
    Kruse P; Rieck P; Sherif Z; Liekfeld A
    Klin Monbl Augenheilkd; 2006 Jun; 223(6):534-7. PubMed ID: 16804825
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The comparative cardiovascular, pulmonary, ocular blood flow, and ocular hypotensive effects of topical travoprost, bimatoprost, brimonidine, and betaxolol.
    Inan UU; Ermis SS; Orman A; Onrat E; Yucel A; Ozturk F; Asagidag A; Celik A
    J Ocul Pharmacol Ther; 2004 Aug; 20(4):293-310. PubMed ID: 15321024
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Allergic contact dermatitis caused by topical eye drops.
    Spaeth GL
    Am J Ophthalmol; 2006 Oct; 142(4):706. PubMed ID: 17011880
    [No Abstract]   [Full Text] [Related]  

  • 34. Inter-visit intraocular pressure range: an alternative parameter for assessing intraocular pressure control in clinical trials.
    Varma R; Hwang LJ; Grunden JW; Bean GW
    Am J Ophthalmol; 2008 Feb; 145(2):336-42. PubMed ID: 18222194
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparison of long-term intraocular pressure fluctuation in patients treated with bimatoprost or latanoprost.
    Simmons ST; Bernstein P; Hollander DA
    Am J Ophthalmol; 2008 Sep; 146(3):473-7. PubMed ID: 18561893
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bimatoprost: establishing its role in glaucoma management.
    Katz LJ
    Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S1-4. PubMed ID: 15016555
    [No Abstract]   [Full Text] [Related]  

  • 37. Corneal sensitivity changes following the instillation of latanoprost, bimatoprost, and travoprost eyedrops.
    Kozobolis VP; Detorakis ET; Maskaleris G; Koukoula SC; Fountoulakis N; Chrysochoou F; Konstas AG
    Am J Ophthalmol; 2005 Apr; 139(4):742-3. PubMed ID: 15808188
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of switching to travoprost on intraocular pressure of uncontrolled chronic open-angle glaucoma patients compliant to previously-used topical medication.
    Holló G; Vargha P; Kóthy P
    Curr Med Res Opin; 2005 Dec; 21(12):1943-8. PubMed ID: 16368044
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of ocular surface side effects of topical travoprost and bimatoprost.
    Alagöz G; Bayer A; Boran C; Serin D; Kükner A; Elçioğlu M
    Ophthalmologica; 2008; 222(3):161-7. PubMed ID: 18497524
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effects of prostaglandin analogues on the blood aqueous barrier and corneal thickness of phakic patients with primary open-angle glaucoma and ocular hypertension.
    Arcieri ES; Pierre Filho PT; Wakamatsu TH; Costa VP
    Eye (Lond); 2008 Feb; 22(2):179-83. PubMed ID: 16936646
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.